Search Results - "Stauffer, V L"

The heterogeneity of antipsychotic response in the treatment of schizophrenia by Case, M, Stauffer, V L, Ascher-Svanum, H, Conley, R, Kapur, S, Kane, J M, Kollack-Walker, S, Jacob, J, Kinon, B J

“…Schizophrenia is a heterogeneous disorder in terms of patient response to antipsychotic treatment. Understanding the heterogeneity of treatment response may…”
Get more information

Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials by Ruff, D. D., Ford, J. H., Tockhorn‐Heidenreich, A., Stauffer, V. L., Govindan, S., Aurora, S. K., Terwindt, G. M., Goadsby, P. J.

“…Background and purpose The efficacy of galcanezumab, a monoclonal antibody for migraine prevention, has been demonstrated in two pivotal trials in patients…”
Get full text

Response to ‘Do different treatment strategies of galcanezumab have similar effect on migraine?’ by Goadsby, P. J., Terwindt, G. M., Ruff, D. D., Ford, J. H., Tockhorn‐Heidenreich, A., Stauffer, V. L., Govindan, S., Aurora, S. K.

Get full text

Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine by KINON, Bruce J, BASSON, Bruce R, GILMORE, Julie A, MALCOLM, Sandra, STAUFFER, Virginia L

“…This study compared the efficacy and safety of 4 therapeutically relevant strategies for switching clinically stable patients from a conventional antipsychotic…”
Get full text

Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia by Fijal, B A, Kinon, B J, Kapur, S, Stauffer, V L, Conley, R R, Jamal, H H, Kane, J M, Witte, M M, Houston, J P

“…Clinical trial data were evaluated for the association between 22 single-nucleotide polymorphisms (SNPs) and response in acutely ill patients diagnosed with…”
Get full text

Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being by Naber, D, Kollack-Walker, S, Chen, J, Stauffer, V L, Kinon, B J, Case, M, Ascher-Svanum, H, Kapur, S, Kane, J M

“…The aim of this study was to determine what variables predict a 'combined treatment outcome' (COMBOUT) in patients with chronic schizophrenia. This analysis…”
Get more information

Potential Macrolide Interaction with Verapamil by Steenbergen, John A, Stauffer, Virginia L

Get full text

Dose response and atypical antipsychotics in schizophrenia by KINON, Bruce J, AHL, Jonna, STAUFFER, Virginia L, HILL, Angela L, BUCKLEY, Peter F

“…Based on information from clinical trials, both the efficacy and adverse effects of conventional antipsychotics in the treatment of schizophrenia are dose…”
Get full text

Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy by Peng, Xiaomei, Ascher-Svanum, Haya, Faries, Douglas E, Stauffer, Virginia L, Kollack-Walker, Sara, Kinon, Bruce J, Kane, John M

“…To compare the cost-effectiveness of treating early responders versus early nonresponders to an atypical antipsychotic (risperidone) and the cost-effectiveness…”
Get full text

Olanzapine Plasma Concentrations After Treatment With 10, 20, and 40 mg/d in Patients With Schizophrenia: An Analysis of Correlations With Efficacy, Weight Gain, and Prolactin Concentration by CITROME, Leslie, STAUFFER, Virginia L, LEI CHEN, KINON, Bruce J, KURTZ, Darcie L, JACOBSON, Jennie G, BERGSTROM, Richard F

“…Objectives of the study were to evaluate the relationship between olanzapine plasma concentrations and efficacy, prolactin, and weight and to assess effects of…”
Get full text

Predictive Value of Early Changes in Triglycerides and Weight for Longer-Term Changes in Metabolic Measures During Olanzapine, Ziprasidone or Aripiprazole Treatment for Schizophrenia and Schizoaffective Disorder: Post Hoc Analyses of 3 Randomized, Controlled Clinical Trials by HOFFMANN, Vicki P, CASE, Michael, STAUFFER, Virginia L, JACOBSON, Jennie G, CONLEY, Robert R

“…The objective of this study was to determine if early changes in triglycerides and weight may be useful in predicting longer-term changes in weight and other…”
Get full text

Early Onset of Antipsychotic Action in Schizophrenia: Evaluating the Possibility of Shorter Acute Efficacy Trials by KINON, Bruce J, LEI CHEN, STAUFFER, Virginia L, SNIADECKI, Jennifer, ASCHER-SVANUM, Haya, KOLLACK-WALKER, Sara, JACOB, Jayanthi, KAPUR, Shitij

“…Extended placebo-controlled clinical trials in schizophrenia research pose an ethical challenge. This study examines factors that have implications for the…”
Get full text

PND44 - Effects of Galcanezumab on Healthcare Resource Utilization and Acute Medication Use in Patients with Migraine: Results from Two Global Phase 3 Clinical Trials by Ford, JH, Foster, SA, Detke, HC, Stauffer, VL, Ruff, DD, Aurora, SK

Get full text

Effects of Galcanezumab on Healthcare Resource Utilization and Acute Medication Use in Patients with Migraine: Results from Two Global Phase 3 Clinical Trials by Ford, JH, Foster, SA, Detke, HC, Stauffer, VL, Ruff, DD, Aurora, SK

Get full text

Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies by Stauffer, Virginia L, Sides, Ryan, Lanteri-Minet, Michel, Kielbasa, William, Jin, Yan, Selzler, Katherine J, Tepper, Stewart J

“…The aim of this study was to compare the usability and patient-rated experiences of an autoinjector with a prefilled syringe in patients with migraine, who…”
Get full text

Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine by Ford, Janet H, Foster, Shonda A, Stauffer, Virginia L, Ruff, Dustin D, Aurora, Sheena K, Versijpt, Jan

“…Effects of galcanezumab, a monoclonal antibody against calcitonin gene-related peptide, on patient satisfaction, health care resource utilization (HCRU), and…”
Get full text

An excitement subscale of the Positive and Negative Syndrome Scale by Lindenmayer, Jean-Pierre, Brown, Eileen, Baker, Robert W., Schuh, Leslie M., Shao, Lixin, Tohen, Mauricio, Ahmed, Saeeduddin, Stauffer, Virginia L.

“…Background: We sought to develop and validate an excitement subscale from the Positive and Negative Syndrome Scale (PANSS) to allow the investigation of…”
Get full text

Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia by Chen, Lei, Ascher-Svanum, Haya, Lawson, Anthony, Stauffer, Virginia L, Nyhuis, Allen, Haynes, Virginia, Schuh, Kory, Kinon, Bruce J

“…This study identified subgroups of patients with schizophrenia who differed on their movement disorder profile and compared their treatment outcomes. Data from…”
Get full text

PMH2 EARLY RESPONSE PREDICTS SUBSEQUENT RESPONSE TO OLANZAPINE LONG-ACTING INJECTIONS IN THE TREATMENT OF SCHIZOPHRENIA by Ascher-Svanum, H, Zhao, F, Nyhuis, A, Lawson, AH, Stauffer, VL, Montgomery, W, Witte, M, Detke, H, McDonnell, DP

Get full text

PMH51 THE COST-EFFECTIVENESS OF EARLY RESPONDERS VERSUS EARLY NON-RESPONDERS TO ATYPICAL ANTIPSYCHOTIC THERAPY by Peng, X, Ascher-Svanum, H, Faries, D, Stauffer, VL, Kollack-Walker, S, Kinon, BJ, Kane, JM

Get full text